BioCatalystFeed / Readout calendar / FDA decisions / Drugs / Disease areas / Companies / Months
KPTIQ upcoming catalysts
Karyopharm Therapeutics Inc: 2 upcoming industry Phase 2/3 trial readout(s) in the next 90 days (1 Phase 3), 0 upcoming FDA decision event(s), and in the last 12 months 4 readout(s) and 1 FDA event(s). Subscribe to KPTIQ (.ics).
Drugs: Selinexor, Rituximab, Gemcitabine, Dexamethasone, Cisplatin, Ruxolitinib, Bendamustine, Ibrutinib, Lenalidomide, Venetoclax, Oxaliplatin
Upcoming FDA decision events
| Date | Event | Status | Company | Drug | Source |
|---|---|---|---|---|---|
| No upcoming PDUFA date or AdCom found. | |||||
Upcoming trial readouts
| Readout | Phase | Sponsor | Trial | Conditions | Status | Enrollment |
|---|---|---|---|---|---|---|
| 2026-12 est. | P2 | Karyopharm Therapeutics Inc KPTIQ | NCT02227251 Selinexor (KPT-330) in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) | Diffuse Large B-cell Lymphoma | active not recruiting | 244 |
| 2026-12 est. | P2/P3 | Karyopharm Therapeutics Inc KPTIQ | NCT04442022 A Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) With or Without Selinexor in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma | Relapsed/Refractory Diffuse Large B-cell Lymphoma | active not recruiting | 501 |
FDA decision events, last 12 months
| Date | Event | Status | Company | Drug | Source |
|---|---|---|---|---|---|
| 2026-04-23 | FDA approval | approved | KARYOPHARM THERAPS KPTIQ | XPOVIO | Approved 2026-04-23: XPOVIO (NDA212306 SUPPL18) |
Trial readouts, last 12 months
| Readout | Phase | Sponsor | Trial | Conditions | Status | Enrollment |
|---|---|---|---|---|---|---|
| 2026-09 est. | P2 | Karyopharm Therapeutics Inc KPTIQ | NCT04562870 A Study to Evaluate Single Agent Selinexor Versus Physician's Choice in Participants With Previously Treated Myelofibrosis | Myelofibrosis | active not recruiting | 112 |
| 2026-05-22 | P3 | Karyopharm Therapeutics Inc KPTIQ | NCT05611931 Selinexor in Maintenance Therapy After Systemic Therapy for Participants With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma | Endometrial Cancer | active not recruiting | 257 |
| 2026-02-20 | P3 | Karyopharm Therapeutics Inc KPTIQ | NCT04562389 Study of Selinexor in Combination With Ruxolitinib in Myelofibrosis | Myelofibrosis | active not recruiting | 353 |
| 2025-12 est. | P1/P2 | Karyopharm Therapeutics Inc KPTIQ | NCT04607772 Study of Selinexor in Combination With Backbone Treatments or Novel Therapies In Participants With Relapsed or Refractory (RR) Diffuse Large B-Cell Lymphoma (DL | Relapsed or Refractory Diffuse Large B-Cell Lymphoma | withdrawn |
Readout = ClinicalTrials.gov primary completion date (sponsor-reported; est. dates often slip; top-line
results usually follow weeks to months later). FDA events: PDUFA dates are extracted from company 8-K filings (SEC EDGAR) and are
company-disclosed and UNVERIFIED - read the filing; AdCom meetings come from Federal Register notices; approvals from Drugs@FDA
(openFDA); complete response letters from openFDA (published with a lag). Tickers are matched by name with a confidence score.
Generated 2026-11-18T17:57:33Z. Same data: bcf readouts search, bcf fda-decisions search, MCP
readout_calendar / fda_decisions. Not investment advice.